Clinical Trials Logo

Short Bowel Syndrome clinical trials

View clinical trials related to Short Bowel Syndrome.

Filter by:

NCT ID: NCT06427642 Recruiting - Clinical trials for Bronchopulmonary Dysplasia

Efficacy Evaluation of UCB-MNCs in the Treatment of Refractory Neonatal Diseases

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

Hypoxic-ischemic encephalopathy (HIE), bronchopulmonary dysplasia (BPD), short bowel syndrome (SBS) are refractory in clinical treatment. Thus, how to better prevent such diseases is currently a key research topic in the international field. The use of cord blood-derived mononuclear cells may promote to save lives and improve patient outcomes.

NCT ID: NCT06391762 Completed - Clinical trials for Short Bowel Syndrome

Level of Deprivation Assessment in a Population of Short-bowel Syndrome Patients With Intestinal Failure

PRECAR-SGC
Start date: December 28, 2023
Phase:
Study type: Observational

The association between social deprivation and chronic disease is regularly examined but there are no data available on patients with intestinal failure due to short bowel syndrome (SBS-IF). First, the investigators aim to characterize this population and then to assess if insecurity is associated with some disease criteria.

NCT ID: NCT06326645 Not yet recruiting - Clinical trials for Short Bowel Syndrome

Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome

Start date: December 1, 2024
Phase: Early Phase 1
Study type: Interventional

The objectives of this study are to evaluate the efficacy and safety of crofelemer treatment in adults affected by Short Bowel Syndrome (SBS) with an ileostomy on parenteral support (PS) in reducing output or PS needs. Crofelemer will be provided as a powder three times daily for 12 weeks and a 4 week follow up. .

NCT ID: NCT06240065 Enrolling by invitation - Short Gut Syndrome Clinical Trials

Predicting Success With Fiber Food Introduction in Short Bowel Syndrome

Start date: April 19, 2024
Phase: N/A
Study type: Interventional

Short bowel syndrome (SBS) is a rare but challenging condition in which patients have insufficient bowel length to meet fluid, electrolyte, and nutrient requirements without parenteral support. The purpose of this study is to determine how well dietary fiber is tolerated in patients with short bowel syndrome compared to patients without short bowel syndrome based on assessment of gastrointestinal symptoms, and corresponding changes in microbiome composition and metabolomics.

NCT ID: NCT06185088 Recruiting - Clinical trials for Short Bowel Syndrome

MENDD Tolerance Assessment Study

Start date: March 6, 2023
Phase: N/A
Study type: Interventional

This study will utilize approved devices in an off-label manner to create forces required to induce intestinal lengthening. Radial and longitudinal forces are both required, and two devices will be used to create forces in order to test tolerability of said forces. This is to provide evidence that humans could tolerate the forces produced by a proposed commercially built device. This study will test the hypothesis that radial and longitudinal forces necessary to produce enterogenesis will cause low levels of discomfort in healthy adults. Approved devices will be utilized in an off-label manner to reproduce forces similar to our novel medical device which is designed to treat short bowel syndrome (SBS). This trial will not be testing a treatment for SBS, and individuals with SBS are ineligible for recruitment.

NCT ID: NCT06102668 Completed - Clinical trials for Short Bowel Syndrome

Survival and PN Dependence in SBS Patients

Start date: January 1, 2012
Phase:
Study type: Observational

Short bowel syndrome (SBS) is a rare condition resulting from the loss of portions of the small intestine, and can cause a spectrum of metabolic and physiologic disturbances.The objective of this study was to determine the longterm survival and parenteral nutrition dependence of adult patients with SBS.

NCT ID: NCT05706012 Completed - Clinical trials for Short Bowel Syndrome

Antithrombotic Management of Acute Mesenteric Ischaemia

Start date: June 30, 2023
Phase:
Study type: Observational

Guidelines on the acute and long-term pharmacological treatment of acute mesenteric ischaemia (AMI) recommend the use of thrombolytic, antiplatelet or anticoagulant therapy depending on the aetiology of AMI and the use of stenting but only few details are given on the choice of the drug, dose and duration of treatment. Besides, recommendations are mainly based on data on coronary, cerebral and other peripheral artery diseases and do also not take into account the altered drug absorption in patients with short bowel syndrome, in which AMI can result.This case-based survey will inform us on the current international clinical practice of long-term antithrombotic management of AMI.

NCT ID: NCT05635747 Enrolling by invitation - Clinical trials for Short Bowel Syndrome

A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB

Start date: September 29, 2022
Phase:
Study type: Observational

Children with inadequate intestinal absorption due to loss of large amounts of small bowel require intravenous nutrition (feeding through the vein) to sustain hydration and nutrition to avoid starvation and dehydration; however, intravenous (IV) nutrition can lead to complications including liver failure. Tube feeding directly to the small intestine avoids the complications of IV nutrition, but fats are not fully digestible due to inadequate bowel function. We propose to predigest the fat using a small cartridge attached to the feeding tube to allow for rapid absorption with the possibility of reducing or eliminating the need for intravenous nutrition. Goal of the observational study is to determine safety and tolerability of Relizorb Enzyme Cartridge for an additional 90 days after the original trial

NCT ID: NCT05561647 Recruiting - Clinical trials for Short Bowel Syndrome (SBS)

A Survey to Assess Participants' and Physicians' Knowledge, Attitudes and Behavior When Using GATTEX

GATTEX KAB
Start date: August 1, 2013
Phase:
Study type: Observational

The main aim of this study is to document the level of knowledge and assess attitudes and behaviors of both participants and physicians regarding the risks and safe use of GATTEX. The survey will be done via internet, telephone, or paper and patients will be able to choose the method that is preferred. No study medicines will be provided to patients in this study.

NCT ID: NCT05535361 Recruiting - Clinical trials for Short Bowel Syndrome

A Feasibility Study to Evaluate Safety & Benefit of Eclipse XL1 System in Adult Patients With SBS

Start date: January 15, 2023
Phase: N/A
Study type: Interventional

The Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System in Adult Patients with Short Bowel Syndrome shall enroll up to 5 Subjects at up to 2 study sites in the United States.